Alaunos Therapeutics Acquires Velaris Therapeutics Amid Nasdaq Delisting Fight
TCRT sits 38% above its 52-week low of $0.719 on elevated volume (4.0× avg).
Summary
Alaunos Therapeutics has acquired Velaris Therapeutics, a move that could reshape its pipeline and strategic direction. The deal comes just days after Nasdaq initiated delisting proceedings against Alaunos for failing to maintain the $2.5 million minimum stockholders' equity requirement. The company's last 10-Q showed a critical cash position of only $0.35 million, raising questions about how the acquisition was financed. Alaunos issued 105,286 Series B and 33,054 Series C preferred shares to Velaris stockholders and agreed to sell $350M of PIPE securities, with closing expected October 14, 2026. The acquisition may bring new assets or technology that could address the company's going concern issues. Separately, Paragon Labs announced leadership additions from Apogee, though the connection to Alaunos is unclear from the headline.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Alaunos issued 105,286 Series B and 33,054 Series C preferred shares to Velaris stockholders and agreed to sell $350M of PIPE securities, with closing expected October 14, 2026.
At the time of this announcement, TCRT was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $0.72 to $4.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.